Haemostasis & Rapid Tests Newsletters April 2015 -01 April 2015
Welcome to 2015 with our latest newsletter full of interesting news from Quadratech
Newsletter Haemostasis May 2014 -20 August 2014
Our latest newsletter full of interesting news
Forthcoming Meeting: Microparticles: Biomarkers of Disease? -13 March 2013
Quadratech is sponsoring a Microparticles Meeting at the University of Leicester Tuesday 21st May 2013 A series of presentations by leading microparticles researchers from the UK and Amsterdam Medical Centre
Article of Interest (Coagulation): Effect of Oral Contraceptive on protein S and TFPI -12 March 2013
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Raps M et al, 2013, Throm Haemost 109(4):[ahead of print] "The effect of oral contraceptives on TFPI and PS is a possible explanation for the increased risk of venous thrombosis associated with oral contraceptives"
Molecular Circuits in Thrombosis and Inflammation. Esmon CT, 2013, Throm Haemost 109 (3):416-420 "In addition to the direct prothrombotic activity of histone-DNA complexes, the complexes trigger activation of the toll-like receptors 2, 4 and 9 thereby increasing inflammatory cytokine formation and fostering thrombotic responses through the mechanisms mentioned previously."
Article of Interest:Vascular Biology -06 February 2013
Early Vascular Alterations in SLE and RA Patients—A Step towards Understanding the Associated Cardiovascular Risk. Jose M et al, PLOS ONE www.plosone.org 1 September 2012 Volume 7 Issue 9
Article of Interest (Coagulation):Factor Concentrates -06 February 2013
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.
Is There a Difference in Anticoagulation Stability Between Domiciliary-Based and Hospital-Based Patients? -08 January 2013
A study of patients in three different monitoring settings showed domiciliary-based patients had the poorest anticoagulation control.
Article of Interest (Coagulation) - Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. -02 January 2013
What is already known about this subject: Observation from clinical studies have demonstrated that: • CYP2C19 genotype does not have a clinically relevant effect on active metabolite concentrations or platelet inhibition in prasugrel-treated subjects • Variability of response to clopidogrel active metabolite and reduced platelet inhibition lead to increased adverse cardiovascular events in patients with acute coronary syndromes
Article of Interest (Coagulation) -The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. -02 January 2013
What is already known about this subject: A number of pharmacokinetics studies have focused on S-warfarin. These have shown that demographic factors, such as bodyweight, genetic factors, such as CYP2C9 genotype, and interacting medicines, particularly amiodarone, contribute to the interindividual estimates of clearance. What this study adds: This study not only reinforces what has previously been learned about S-warfarin, but also provides an insight into the pharmacokinetics of R-warfarin.